New combo therapy targets hard-to-treat mesothelioma

This study tests a new two-step treatment for people with malignant pleural mesothelioma, a rare and serious cancer of the lung lining. First, doctors use a special light therapy during a scope procedure to kill cancer cells. Then, patients receive an immunotherapy drug called nivolumab to help the immune system attack remaining cancer. The goal is to see if this combination is safe and feasible for 20 patients whose cancer has returned after chemotherapy.